Relapse, poor survival in leukemia linked to genetic mutations that persist in remission

25 agosto 2015

For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations — detected after initial treatment with chemotherapy — are associated with an increased risk of relapse and poor survival. Using genetic profiling to study bone marrow samples from patients with acute myeloid leukemia (AML), researchers found that those whose cells still carried mutations 30 days after the initiation of chemotherapy were about three times more likely to relapse and die than patients whose bone marrow was cleared of these mutations.